1050239-46-7

Upstream product

• 1050239-39-8 diethyl 2-({2-[5-fluoro-3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}methyl)propane-1,3-dioate 
• 1050239-42-3 ethyl 3-{2-[5-fluoro-3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}propanoate 
• 1005336-33-3 4-(chloromethyl)-2-[5-fluoro-3-(trifluoromethyl)phenyl]-1,3-oxazole 
• 1050239-43-4 3-{2-[5-fluoro-3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}propan-1-ol 
• 115-86-6 phosphoric acid triphenyl ester 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION

Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.

ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS

Disclosed are isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for use treating in mammals suffering from psychiatric disorders such as, for example, depression, generalized anxiety, social phobia, panic disorder, and sleep disorders.

ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION

Disclosed are novel isoflavone derivatives having the structure of Formula I which are useful as ALDH-2 inhibitors for treating mammals for dependence upon drugs of addiction, for example addiction to dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and alcohol.